Oluwaseyi Akinpelu’s Post

*Hello Monday: Embrace Diversity of Thought* As we step into a new week, let's embrace the diversity of thought that enriches our lives, much like the varied branches of scientific knowledge. Each day presents an opportunity to explore new ideas, challenge our perspectives, and contribute to a collective understanding that drives innovation and growth. At Helix Biogen Institute, we believe in the power of diverse thinking. Our commitment to fostering a collaborative environment where unique ideas flourish is at the heart of our scientific endeavors. This week, we encourage you to approach your tasks with an open mind and a willingness to learn from the myriad of perspectives around you. Remember, it is through the fusion of different viewpoints that we can achieve breakthroughs and advance our knowledge. Let's make this week a testament to the strength found in diversity and the endless possibilities it brings. Wishing you a productive and insightful week ahead! Dr. Oladipo Elijah Kolawole (Ph.D) Helix Biogen Institute #HelloMonday #DiversityOfThought #ScientificKnowledge #Innovation #HelixBiogenInstitute #CollaborativeEnvironment #NewWeekNewIdeas

#challengeDay10 at Helix Biogen Institute written or multiple choice questions!? Certainly! When it comes to assessing knowledge, I find written questions to be more effective and insightful than multiple-choice questions. Written questions allow for a deeper exploration of a person's understanding, encouraging critical thinking and comprehensive responses. They provide an opportunity for individuals to express their knowledge in their own words, showcasing a more authentic grasp of the subject matter. Additionally, written questions offer a flexible format, accommodating a wider range of possible answers and fostering a richer evaluation of an individual's expertise. #written #understanding #challengeday10 Helix Biogen Institute Dr. Oladipo Elijah Kolawole (Ph.D) Boluwatife Ayobami Irewolede Glory Jesudara Oluwasanya Stephen Adeyemo

Embrace Evolution: Thrive This Week! Each day presents new opportunities for growth and improvement. You can navigate your week with resilience and innovation. Embrace change, learn from every experience, and continue to adapt. This mindset will empower you to not only face challenges but to transform them into stepping stones for success. Here's to a week of evolution and thriving in every endeavor! Helix Biogen Institute #MotivationMonday #BiologyLovers #DailyInspiration #EvolveAndThrive #HelloMonday #AdaptAndSucceed #WeeklyMotivation #BiologyInspiration #GrowthMindset #OvercomeChallenges #ThriveOn

Believe in your potential this week! You have 7 days to: ✨ Learn something new ✨ Take a step towards your goal ✨ Build meaningful connections ✨ Practice self-care ✨ Embrace challenges as opportunities Remember, your potential is limitless. Go out there and crush it! Make this week count! Dr. Oladipo Elijah Kolawole (Ph.D) Helix Biogen Institute #MondayMotivation #InnovationDriven #ExperimentAndExcel #GroundbreakingAchievements #NewWeekNewObjectives #SuccessOriented #ProfessionalExcellence #ProductivityAndPerformance

Experiment with new ideas, test your limits, and create something extraordinary. Remember, every challenge is an opportunity to conduct an experiment of success. Mix curiosity, determination, and creativity to produce an amazing outcome. And when faced with failures, use them as data points to refine your approach. This week, let's turn obstacles into experiments and create a remarkable story of growth and achievement. Make this week count! Make it your laboratory of success! Helix Biogen Institute #HelloMonday #MakeItHappen #LaboratoryOfLife

As we approach the end of the year, I want to share a big thank you to my 28,000 colleagues around the world for helping realize our purpose in 2023. I’ve been reflecting on this year a lot. It was full of impact – driven by our employees, for our customers and, ultimately, to serve patients. It was also a year of transition for the entire life science industry. Transitions can be challenging, but they can also be powerful – bringing a new direction, new ways of working or new methods to innovate. All of this brings opportunity. Opportunity to lead in new ways and, more importantly, opportunity to create impact. Which is exactly what our employees did. To highlight just a few milestones our Merck Life Science team achieved this year, we:  • Enhanced our product and service offerings through key launches in innovative areas, such as mRNA, single-use bioprocessing and biosafety testing  • Invested in our capabilities and capacity across our value chain in Europe, Asia and the US  • Made significant progress in reducing our carbon footprint while creating more sustainable packaging and products, including adding more than 500 greener alternative products • Reached more than 80,000 students through our Curiosity Cube and our other science education programs – sparking curiosity for the next generation of scientists Next year will bring new challenges and continued transition, but I’m confident it will also bring new opportunities for our people to do what they do best: deliver on our purpose of impacting life and health with science. 

As this year's JP Morgan healthcare week is behind us, the time has come for life science professionals to set their sights on next year's event. 🔍 Discover why attending JP Morgan should be a top priority for Swedish companies and learn from the experiences of Evelina Vågesjö from ILYA Pharma, Anne-Marie Wenthzel from Sprint Bioscience and SwedenBIOs Marjo Puumalainen who have attended JP Morgan in the past. 💡 Find out how SwedenBIO supports member companies during the bustling week, from discounted access to partnering conferences to invaluable meeting facilities. 📝 Read the article here: https://lnkd.in/dStdUjG2 #JPmorganHealthcareWeek #LifeScienceProfessionals #Networking #Partnerships #GlobalOpportunities #IndustryGrowth

 “While some are waiting for the IPO’s to come, there are a lot of interesting listed companies here today, you can invest in!”- Peter Legind-Hansen, Nasdaq The flagship indexes in the US are in all-time high and OMX Nordic is close to all time high despite a still little high interest rate and inflation. So, there IS a lot of money out there and the future and trends are looking brighter, yet there is still a lot of selectivity.  Already listed biotech and healthcare companies are more mature now and closer to reaching their ultimate goals but have much lower share prices than in 2021 due to the risk appetite and cost of capital. Two-day conference with Experts insights from international investors, successful dealmakers, Market Access experts – spiced with pitches from innovative Nordic biopharma companies – organized by BioStock - Connecting Innovation and Capital today and tomorrow. A conference connecting Nordic growth stage biopharma companies with global investors, expanding into new markets, creating global partnerships… We have a lot to offer and potential in the Nordic life science sector. Medicon Valley Alliance our mission is to strengthen our eco-system but also calling for increased collaboration within life science triple helix in the Nordics. Thank you to BioStock - Connecting Innovation and Capital for the invitation for these insightful days! HealthCap Agio Capital Sound Bioventures Sunstone Life Science Ventures Jonas Söderström

Under the motto "Seed and Succeed 🌱," BIOTECH AUSTRIA invited to its 3rd Biotech Circle Austria at the Wiener Boerse this morning. Norbert Bischofberger delivered an inspiring talk, addressing the disparities between the biotech funding landscape in the US and Europe, followed by a lively panel discussion, with some thought-provoking questions. 𝘋𝘰 𝘸𝘦 𝘴𝘰𝘸 𝘴𝘦𝘦𝘥𝘴 𝘴𝘶𝘤𝘤𝘦𝘴𝘴𝘧𝘶𝘭𝘭𝘺 𝘣𝘶𝘵 𝘧𝘢𝘪𝘭 𝘵𝘰 𝘴𝘶𝘤𝘤𝘦𝘦𝘥? 𝘐𝘴 𝘴𝘤𝘪𝘦𝘯𝘤𝘦 𝘪𝘯 𝘈𝘶𝘴𝘵𝘳𝘪𝘢 𝘮𝘦𝘳𝘦𝘭𝘺 "𝘨𝘰𝘰𝘥" 𝘳𝘢𝘵𝘩𝘦𝘳 𝘵𝘩𝘢𝘯 "𝘨𝘳𝘦𝘢𝘵"? I believe that we have fantastic scientific achievements 🔬 and success stories in Austria, yet perhaps we sometimes lack the confidence(?) to effectively communicate them to a wider audience. Let’s dare to be a little bit bolder, think bigger, and also embrace failures without fear. We can only truly convince others of Austria being a great place for biotech when we are convinced ourselves! Thank you, BIOTECH AUSTRIA for organizing such a great event! #BCA2024 #BiotechAustria #Science

Had the pleasure of spending some time with the AbbVie market access, HTA, and governmental affairs teams to reflect on where the life science industry is headed, building on a presentation I gave earlier this year on navigating the global life science landscape, but with a bit more time to put more "flesh on the bone" in some areas - 💡 Lifestyle medicine. We know that lifestyle and behavioural interventions can have an outsized impact on health compared to pure medical care. But prescribing food, sleep or physical activity - or what some call "lifestyle medicine" - is actually not new. Take PAP (physical activity on prescription) for example. Sweden has a model for it that is considered best practice by WHO and EU, Swedes are keen on it (8 in 10 would prefer it to medication), but yet it's not being used very widely, with the main obstacle being the lack of time for healthcare staff to learn about the method and actively use it. 💡 Longevity medicine. An emerging field that challenges ageing itself in a bid to not just live longer, but live healthier. There are two perspectives in this - slowing down ageing (e.g. research efforts to address "12 hallmarks of ageing" that, if treated, could significantly slow down ageing itself); or, a bit more radically, reversing ageing itself (linked to a biological "ageing clock" comprised of four genes discovered by Nobel scientist Shinya Yamahaka, that could reprogram cells back to their embryonic, stem cell state). Interesting science, but also with lots of implications for society at large. 💡 Precision medicine. As in the case of cell and gene therapies - again, an area with huge potential to address real unmet needs, but the business model has still proven to be elusive for profit-making companies. Could the solution be in the non-profit sector? For example, just last month, the Italian non-profit Telethon Foundation announced that it will commercialise Strimvelis, a gene therapy addressing a form of severe combined immunodeficiency at a price tag of 594 000 EUR for a one-time, lifelong cure, but which was abandoned by two companies (GSK and Orchard Therapeutics) before being picked up by Telethon Foundation. Could this be the new business model for such therapies, and will it be sustainable? As usual I probably left the room with more questions than answers 😅 But allowing us that space might actually be more healthy than we think. In a purpose-driven field like life science and healthcare that seeks to benefit mankind and society, taking time to formulate the right questions, and question the underlying assumptions that define our conclusions (are they still valid and relevant today?) can be immensely valuable in ensuring we put our resources in the right places. As Einstein said, “If I were given one hour to save the planet, I would spend 59 minutes defining the problem and one minute resolving it.” Thank you Mia Tillgren Moreau for inviting me to spend the day with you and your colleagues!